Bioentrepreneur | Published:

Building for big pharma

Nature Biotechnology volume 31, pages 284287 (2013) | Download Citation

With acquisition the most likely exit for today's biotech investors, it pays to keep current with the tastes of pharmaceutical firms when launching a venture.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Big Pharma Mega-Mergers 1995–2014,

  2. 2.

    & Eur. Neuropsychopharmacol. 21, 495–499 (2011).

  3. 3.

    Tufts Center for the Study of Drug Development. Impact report: new or modified indications for existing drugs have steadily increased in U.S. 13(2) (Tufts University, March/April 2011).

  4. 4.

    Silicon Valley Bank. Continued rebound: trends in life science M&A. <> (July 2012).

  5. 5.

    Life sciences M&A sees fewer billion dollar deals. The Burrill Report (4 January 2013).

Download references

Author information


  1. Asiya Giniatullina is analyst, Marco Boorsma is principal and Geert-Jan Mulder is general partner at Forbion Capital Partners, Naarden, The Netherlands.

    • Asiya Giniatullina
    • , Marco Boorsma
    •  & Geert-Jan Mulder
  2. Sander van Deventer is general partner at Forbion Capital Partners and professor in the Department of Gastroenterology, Leiden University Medical Center, Leiden, The Netherlands.

    • Sander van Deventer


  1. Search for Asiya Giniatullina in:

  2. Search for Marco Boorsma in:

  3. Search for Geert-Jan Mulder in:

  4. Search for Sander van Deventer in:

Competing interests

M.B., G-J.M. and S.v.D. are employed by Forbion Capital Partners.

Corresponding author

Correspondence to Sander van Deventer.

Supplementary information

About this article

Publication history



Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing